Stem cell scandal reverberates in U.S.
By San Diego Union Tribune,
San Diego Union Tribune
| 12. 18. 2005
S. Korea controversy leads to calls for more oversight
As a South Korean scientist defends against mounting accusations that he falsified evidence in a breakthrough stem cell study, researchers in California said the controversy has caused significant damage to a promising and fledgling field.
Doubts about Hwang Woo-suk's claims that he cloned human cells to create embryonic stem cells have made scientists wonder whether the prospect might remain elusive for years. Researchers and doctors hope to use this process to genetically tailor stem cells for patients suffering from such diseases as Parkinson's, diabetes and multiple sclerosis.
"It's a black eye on the whole world of science," Richard Murphy, president of the Salk Institute in La Jolla, said. "Exciting areas of research are always competitive . . . but healthy competition never justifies sloppy research, cutting corners or dishonest behavior."
In California, where voters approved $3 billion to jump-start stem cell research, the South Korean controversy has led to renewed calls for more oversight of publicly funded science.
Meanwhile, San Diego biologists say the scandal shows why the United States needs...
Related Articles
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...